La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Nuwellis a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Nuwellis..

Nuwellis (NASDAQ:NUWE) Azioni, Catena delle Opzioni

Nuwellis

Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

Nuwellis Inc

As the race for satellite internet heats up, major players like Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are staking their claim in a market projected to be worth <a href="https://www.benzinga.com/news/space/25/06/46012441/amazon-retrains-warehouse-workers-for-satellite-jobs-it-really-is-life-changing-says-project-kuiper-technician">$40 billion by 2030.</a>
Bank of America Securities analyst Justin Post <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Buy</a> on Amazon with a price forecast of $248 on Thursday.
Project Kuiper has remained a top management growth initiative despite Amazon&#8217;s cost-focused agenda, and satellite launches began in the second quarter, Post noted. On its Website, Amazon has indicated that it expects to offer consumer service in late 2025, though timing is still uncertain, the analyst said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46252872/why-amazon-lags-its-peers-in-2025" rel="noreferrer noopener">Why Amazon Lags Its Peers In 2025</a>
In his report, the analyst refreshed his views on launch costs and near-term expense impact from network build, the Project Kuiper business, potential synergies with Amazon, competitive landscape, revenue potential, and potential subscriber breakeven level assuming a 5-year satellite replacement cycle.
Amazon&#8217;s FCC license calls for 1,618 satellites to be deployed by July 2026, though Post noted an extension is possible given launch delays. Amazon completed the first two launches with 54 satellites in the second quarter of 2025, and the analyst expects an accelerated launch rate in the second half of 2025 (3 launches in the third quarter) and 2026.
He estimated that Amazon could spend $23 billion to build its entire constellation, using various public industry estimates, excluding consumer equipment costs.
In the near term, Post estimated over $600 million in constellation expense in the second quarter, ramping to ~$800 million in the third quarter and then growing to $1.1 billion in the fourth quarter of 2025 (before capitalization starts in the first quarter of 2026).
Amazon&#8217;s website indicates that consumer availability could begin in the fourth quarter, but a delay seems possible, the analyst said. He also had a scenario where capitalization starts later, in the third quarter of 2026.
He noted that 2.6 billion people globally lack broadband internet access, and BCG sees a $40 billion 2030 revenue potential for the global satellite communications service market.
Based on Post&#8217;s market assumptions, and assuming Amazon has just a 30% consumer share (Starlink already has 6 million subscribers), the analyst noted a $7.1 billion 2032 revenue potential for Amazon.
He also expects Kuiper to have synergies with Amazon&#8217;s logistics network, and the project to generate additional revenues from AWS&#8217;s enterprise and government customers. Post noted a compelling opportunity and potentially strong long-term margins given high start-up costs.
Post projected fiscal 2025 sales of $696.81 billion and EPS of $6.07.
AMZN Price Action: Amazon.com shares were up 0.09% at $222.75 at the time of publication Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46333941/meta-has-gained-26-in-2025-can-the-rally-continue" target="_blank" rel="noreferrer noopener">Meta Has Gained 26% In 2025, Can The Rally Continue?</a></li>
</ul>
Photo: Shutterstock

News

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

AMZN

How Project Kuiper Could Reshape Amazon's Future, Tap Into $40 Billion Demand

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) supplemental Biologics License Application (sBLA) for Spikevax, the company&#8217;s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
The company&#8217;s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46168811/modernas-mrna-flu-vaccine-outperforms-standard-shots" rel="noreferrer noopener">Moderna&#8217;s mRNA Flu Vaccine Outperforms Standard Shots</a>
&#8220;COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,&#8221; said Stéphane Bancel, CEO of Moderna. &#8220;We appreciate the FDA&#8217;s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.&#8221;
Moderna<a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" rel="noreferrer noopener"> expects</a> to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) have requested that London's Court of Appeal reverse a previous decision that found their COVID-19 vaccine to be in violation of a Moderna patent.
In July 2024, the High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech's Comirnaty <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">vaccine had infringed on it</a>.
Reuters reported that Pfizer and Moderna are trying to challenge a ruling that upheld a patent, after Judge Richard Meade allowed them to appeal his decision.
They argue that Moderna&#8217;s mRNA technology was simply a clear next step based on earlier research, so the patent shouldn&#8217;t be valid. However, Moderna believes the judge made the right decision and that the ruling should remain in place.
An alliance of medical and public health organizations filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Kennedy has launched an "assault on science, public health, and evidence-based medicine" through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children <a href="https://www.benzinga.com/news/health-care/25/07/46303191/medical-groups-sue-rfk-jr-for-assault-on-science-over-unlawful-covid-19-vaccine-rollbacks" target="_blank" rel="noreferrer noopener">and pregnant individuals</a>.
According to a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration's (FDA) top vaccine official, overruled agency scientists to limit the approval of two COVID-19 vaccines, despite internal recommendations to clear <a href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" target="_blank" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">the balance of risks and benefits</a>.
Price Action: MRNA stock is up 3.60% at $33.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/07/46345543/klotho-stock-delivers-1222-biotech-blowout-opportunity-or-bubble" target="_blank" rel="noreferrer noopener">Klotho Stock Delivers 1,222% Biotech Blowout: Opportunity or Bubble?</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Movers

General

BNTX

MRNA

NVAX

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

Goldman Sachs analyst Corinne Johnson reinstates ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and announces $33 price target.

Initiation

AVBP

Goldman Sachs Reinstates Buy on ArriVent BioPharma, Announces $33 Price Target

Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) with a Buy and announces $10 price target.

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Goldman Sachs Reinstates Buy on Amylyx Pharmaceuticals, Announces $10 Price Target

HSCS

HeartSciences Shares Halted On Circuit Breaker To The Downside, Stock Now Up 19.0%

CIGL

Concorde International Group Shares Halted On Circuit Breaker, Stock Now Down -86.5%

B. Riley Securities analyst Lucas Pipes maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $15 to $22.

IREN

B. Riley Securities Maintains Buy on IREN, Raises Price Target to $22

B. Riley Securities analyst Nick Giles maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and lowers the price target from $3 to $2.

B. Riley Securities Maintains Buy on Canaan, Lowers Price Target to $2

<a href="https://www.dallasfed.org/fed/events/2025/25waller">https://www.dallasfed.org/fed/events/2025/25waller</a>

Macro Notification

Politics

Economics

Fed's Waller Says Tariffs Increase Prices One Time, Central Banks Can Look Through That;  Tariff Effects Not Zero But Are Not Large Either; Has Been Arguing A Pretty Restrictive Policy Rate Can Come Down; Unemployment Is Around Long Run Level; Retierates Case For Why July Rate Cut Could Happen, Says An Easing Would Not Be Political

Correction: Needham analyst John Todaro downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Hold.(Price Target removed)

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Correction: Needham Downgrades Core Scientific to Hold (Price Target removed)

B. Riley Securities analyst Lucas Pipes maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and lowers the price target from $18 to $17.

BTDR

B. Riley Securities Maintains Buy on Bitdeer Technologies, Lowers Price Target to $17

<a href="https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html" title="https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html">https://www.nytimes.com/2025/07/10/us/politics/iran-attacks-damage.html</a>

Macro Economic Events

Global

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

'Some of Iran's Enriched Uranium Survived Attacks, Israeli Official Says' - NY Times

B. Riley Securities analyst Christopher Souther maintains Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) with a Buy and raises the price target from $6 to $10.

AMPX

B. Riley Securities Maintains Buy on Amprius Technologies, Raises Price Target to $10

On Wednesday, Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported net sales of $26.44 billion for the retail month of June, which includes the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46333348/costco-shares-rise-after-sales-climb-8-in-june" rel="noreferrer noopener">five-week period ending July 6</a>.
Net sales for the month were up 8% on a year-over-year basis.
The membership-based retailer said total company comparable sales were up 5.8%.
Bank of America (BofA) Securities writes overall, COST's June U.S. core comp came in at +5.5%, slightly below the Street's +6.0% per consensus Metrix, but ahead of buy-side expectations of ~5.0%.
U.S. traffic was +2.8% and total enterprise-wide traffic was +3.4%, while average ticket increased +2.8% YOY (ex-gas deflation and FX).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46348041/is-costcos-winning-streak-built-to-last-during-economic-turmoil" rel="noreferrer noopener">Is Costco&#8217;s Winning Streak Built To Last During Economic Turmoil?</a>
Looking ahead, the tough comparisons due to high gold prices should ease by August. BofA also expects the negative impact from store overlap (cannibalization) to gradually lessen to a more typical range of 20-30 basis points by year-end.
Additionally, the drop in store traffic caused by lower gas prices year-over-year is likely to have peaked, as the steep comparisons should ease by August or September. Current gas prices also suggest mild inflation by October.
As a result, the negative sentiment from momentum investors who viewed Costco as a &#8220;source of funds&#8221; to sell should start to fade, although BofA said they will still be watching how growth stocks perform compared to value stocks and the Russell 2000.
Analyst Christopher Horvers maintains an Overweight rating on Costco, viewing it as a key investment due to its strong global performance, consistent market share growth and exposure to a rebound in large-item spending, which accounts for approximately 20% of its core sales.
He also notes the early benefits of Costco&#8217;s growing advertising business. Horvers says Costco stands out even among top consumer companies.
Unlike other major retailers, Costco has been successful in every country it has entered. Its membership-based model is one of the strongest in retail, comparable to leading auto parts retailers, with Costco clearly leading the market.
BofA maintains the Overweight rating with a price forecast of $1,115. Check out <a href="https://www.benzinga.com/quote/COST/analyst-ratings" target="_blank" rel="noreferrer noopener">other analyst stock ratings</a>.
Price Action: COST stock is down 0.58% at $976.38 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46346078/microsoft-stock-is-trending-thursday-whats-going-on" target="_blank" rel="noreferrer noopener">Microsoft Stock Is Trending Thursday: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Retail Sales

COST

BofA Sticks With Overweight On Costco, Sees Easing Headwinds Ahead

B. Riley Securities analyst Christopher Souther maintains Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a Buy and raises the price target from $12 to $17.

ENVX

B. Riley Securities Maintains Buy on Enovix, Raises Price Target to $17

B. Riley Securities analyst Dave Kang maintains AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) with a Buy and lowers the price target from $4.5 to $4.3.

AXTI

B. Riley Securities Maintains Buy on AXT, Lowers Price Target to $4.3

Fed's Waller Says Stablecoins Could Depress Demand For Cash, Dollar Could Be More Widely Used

Oppenheimer analyst Leland Gershell maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform and raises the price target from $76 to $110.

RYTM

Oppenheimer Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $110

Deep-pocketed investors have adopted a bullish approach towards Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RCL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for Royal Caribbean Gr. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 8 are puts, totaling $248,926, and 18 are calls, amounting to $1,297,740.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $140.0 to $440.0 for Royal Caribbean Gr over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Royal Caribbean Gr options trades today is 146.09 with a total volume of 829.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Royal Caribbean Gr's big money trades within a strike price range of $140.0 to $440.0 over the last 30 days.
<h3>Royal Caribbean Gr Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752170470_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$133.0</td>
<td>$133.0</td>
<td>$133.0</td>
<td>$240.00</td>
<td>$332.5K</td>
<td align="right">90</td>
<td align="right">25</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$108.95</td>
<td>$108.0</td>
<td>$108.0</td>
<td>$280.00</td>
<td>$259.2K</td>
<td align="right">65</td>
<td align="right">29</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$46.95</td>
<td>$46.6</td>
<td>$46.6</td>
<td>$300.00</td>
<td>$139.8K</td>
<td align="right">187</td>
<td align="right">32</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$325.00</td>
<td>$50.0K</td>
<td align="right">87</td>
<td align="right">25</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$38.7</td>
<td>$38.4</td>
<td>$38.7</td>
<td>$350.00</td>
<td>$46.4K</td>
<td align="right">97</td>
<td align="right">13</td>
</tr>
</tbody>
</table>

<h3>About Royal Caribbean Gr</h3>
Royal Caribbean is the world's second-largest cruise company by revenues, operating 67 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021 and plans to launch its new Celebrity River Cruise brand in 2027.
Having examined the options trading patterns of Royal Caribbean Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Royal Caribbean Gr Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 969,065, the RCL's price is up by 2.3%, now at $341.25. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 19 days.</li>
</ul>
<h3>What The Experts Say On Royal Caribbean Gr</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $358.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Royal Caribbean Gr, which currently sits at a price target of $400. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Royal Caribbean Gr with a target price of $358. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Hold rating for Royal Caribbean Gr, targeting a price of $315. 
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Outperform rating on Royal Caribbean Gr with a target price of $360. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Royal Caribbean Gr, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

A Closer Look at Royal Caribbean Gr's Options Market Dynamics

Investors with a lot of money to spend have taken a bullish stance on Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with EL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Estee Lauder Cos.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $58,975, and 14 are calls, for a total amount of $833,361.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $150.0 for Estee Lauder Cos over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Estee Lauder Cos's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Estee Lauder Cos's whale trades within a strike price range from $65.0 to $150.0 in the last 30 days. 
<h3>Estee Lauder Cos Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752170465_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$20.0</td>
<td>$19.55</td>
<td>$20.0</td>
<td>$80.00</td>
<td>$300.0K</td>
<td>1.6K</td>
<td align="right">161</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$6.1</td>
<td>$3.95</td>
<td>$5.51</td>
<td>$125.00</td>
<td>$110.2K</td>
<td>344</td>
<td align="right">200</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$11.25</td>
<td>$10.65</td>
<td>$11.25</td>
<td>$85.00</td>
<td>$67.5K</td>
<td>1.7K</td>
<td align="right">1</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$85.00</td>
<td>$47.4K</td>
<td>1.2K</td>
<td align="right">290</td>
</tr>
<tr>
<td>EL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$40.8K</td>
<td>1.0K</td>
<td align="right">224</td>
</tr>
</tbody>
</table>

<h3>About Estee Lauder Cos</h3>
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (51% of fiscal 2024 sales), makeup (29%), fragrance (16%), and hair care (4%) categories, with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 30% of revenue from the Americas, 39% from Europe, the Middle East and Africa (including travel retail), and 31% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Having examined the options trading patterns of Estee Lauder Cos, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Estee Lauder Cos Standing Right Now?</h3>
<ul>
<li>With a volume of 3,648,953, the price of EL is up 6.18% at $91.96. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Estee Lauder Cos</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $98.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $110. 
&#x2A; An analyst from Deutsche Bank has elevated its stance to Buy, setting a new price target at $95. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Estee Lauder Cos, targeting a price of $100. 
&#x2A; An analyst from HSBC upgraded its action to Buy with a price target of $99. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Estee Lauder Cos with a target price of $90. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Estee Lauder Cos options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Behind the Scenes of Estee Lauder Cos's Latest Options Trends

Management

Press Releases

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

Earnings

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

Legal

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

IPOs

Nuwellis Announces Pricing of $4.3 Million Underwritten Public Offering

Financing

Nuwellis Announces Closing of $5.0 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Nuwellis Appoints John Erb as Chief Executive Officer

NUWE

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

HeartBeam

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Nuwellis

Nuwellis (NUWE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO